Company Analysis

Sagimet Biosciences Inc. (SGMT)

Nasdaq: SGMT · Pharmaceutical Preparations · San Mateo, CA · filing with the SEC since 2007
Grade4.5
◀ Past 3.8● Present 4.4▶ Future 5.1
6 est.

Who runs Sagimet Biosciences Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Happel David
President & CEO. First filing Jul 2023, latest Jul 22, 2026, 6 filings in all.
Officers reporting now
6
of 11 people with a filing in the last fifteen months
Directors reporting now
5
18 people on the record since 2023
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Kemble GeorgeExecutive ChairmanJul 2023Aug 17, 20264 · $4.2M
Happel DavidPresident & CEOJul 2023Jul 22, 20262 · $600,000
Rozek ElizabethChief Legal & Admin. OfficerJul 2023Jul 22, 20262 · $100,000
Chauche ThierryChief Financial OfficerMay 2024Jun 1, 20261 · $0.00
Grauer AndreasChief Medical OfficerMay 2026Jun 1, 2026none
Martins Eduardo BrunoChief Medical OfficerJul 2023Feb 20, 20261 · $0.00
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Grammer Elizabeth AdirectorJul 2023Jun 15, 2026none
Hoelscher Paul W.directorApr 2024Jun 15, 2026none
Jarrett JenniferdirectorAug 2024Jun 15, 2026none
Phillips Anne M.directorAug 2024Jun 15, 2026none
Seidenberg Beth CdirectorJul 2023Jun 15, 2026none
Earlier names on the record15, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton SGMT · research, not advice